You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Pomalidomide

Showing 51 - 75 of 253
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Multiple Myeloma, Renal Impairment, Tumors, Plasma Cell Trial in Greece (Isatuximab, Pomalidomide, Dexamethasone)

Not yet recruiting
  • Multiple Myeloma
  • +7 more
  • Athens, Greece
  • +5 more
Mar 17, 2022

Relapsed and/or Refractory Multiple Myeloma Trial in Canada (GSK2857916 with Pomalidomide and Dexamethasone)

Recruiting
  • Relapsed and/or Refractory Multiple Myeloma
  • GSK2857916 with Pomalidomide and Dexamethasone
  • Edmonton, Alberta, Canada
  • +8 more
Feb 14, 2022

Plasma Cell Myeloma Trial in Atlanta (Carfilzomib, Dexamethasone, Pomalidomide)

Recruiting
  • Plasma Cell Myeloma
  • Atlanta, Georgia
    Emory University Hospital/Winship Cancer Institute
Oct 5, 2021

Multiple Myeloma, Refractory Multiple Myeloma, Multiple Myeloma in Relapse Trial in Boston (Daratumumab, Carfilzomib,

Recruiting
  • Multiple Myeloma
  • +3 more
  • Boston, Massachusetts
  • +2 more
Oct 28, 2021

Multiple Myeloma Trial in Worldwide (ACY-241, Pomalidomide, Dexamethasone)

Active, not recruiting
  • Multiple Myeloma
  • Tucson, Arizona
  • +24 more
Dec 15, 2022

Multiple Myeloma Trial in Canada, United States (Pomalidomide, Carfilzomib, dexamethasone)

Recruiting
  • Multiple Myeloma
  • Pomalidomide
  • +3 more
  • Chicago, Illinois
  • +4 more
Jan 7, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Duarte (Dexamethasone, Leflunomide, Pomalidomide)

Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Duarte, California
    City of Hope Medical Center
Jan 10, 2022

Neurofibromatosis Type 1, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Visual Pathway Glioma Trial in United

Completed
  • Neurofibromatosis Type 1
  • +4 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Los Angeles, California
  • +11 more
Apr 22, 2022

Multiple Myeloma Trial (Elotuzumab, Pomalidomide)

Withdrawn
  • Multiple Myeloma
  • (no location specified)
Aug 18, 2021

Multiple Myeloma Trial (Daratumumab, Cyclophosphamide, Pomalidomide)

Not yet recruiting
  • Multiple Myeloma
  • (no location specified)
Oct 8, 2021

Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Phoenix, Jacksonville, Rochester

Recruiting
  • Plasma Cell Myeloma
  • +3 more
  • Bone Marrow Biopsy
  • +3 more
  • Phoenix, Arizona
  • +2 more
Jan 18, 2023

Multiple Myeloma Trial in United States (Elotuzumab, Pomalidomide, Bortezomib)

Active, not recruiting
  • Multiple Myeloma
  • Boston, Massachusetts
  • +5 more
Oct 28, 2021

Multiple Myeloma in Relapse Trial in Denver, Saint Louis, Toronto (Elotuzumab, Pomalidomide, Dexamethasone)

Active, not recruiting
  • Multiple Myeloma in Relapse
  • Denver, Colorado
  • +2 more
Oct 14, 2021

Multiple Myeloma Trial in Atlanta, Boston (ACE-011, Lenalidomide, Dexamethasone)

Active, not recruiting
  • Multiple Myeloma
  • Atlanta, Georgia
  • +3 more
Oct 28, 2021

Relapsed Refractory Multiple Myeloma Trial in United States (Abemaciclib, dexamethasone, ixazomib, pomalidomide, Enasidenib,

Recruiting
  • Relapsed Refractory Multiple Myeloma
  • Abemaciclib, dexamethasone, ixazomib, pomalidomide
  • +7 more
  • Phoenix, Arizona
  • +16 more
Sep 9, 2021

Multiple Myeloma Trial in United Kingdom (Pomalidomide, Dexamethasone, Cyclophosphamide)

Active, not recruiting
  • Multiple Myeloma
  • Pomalidomide
  • +2 more
  • Belfast, United Kingdom
  • +20 more
May 24, 2022

Multiple Myeloma, First Relapse Trial in France (PCD, Autologous transplantation (ASCT))

Active, not recruiting
  • Multiple Myeloma
  • First Relapse
  • PCD
  • Autologous transplantation (ASCT)
  • Amiens, France
  • +29 more
Jul 13, 2022

Hematological Malignancy, Solid Tumor Trial (OT-A201, IMids, Bevacizumab)

Not yet recruiting
  • Hematological Malignancy
  • Solid Tumor
  • (no location specified)
Apr 24, 2023

Recurrent Plasma Cell Myeloma Trial in United States (Daratumumab, Dexamethasone, Pomalidomide)

Withdrawn
  • Recurrent Plasma Cell Myeloma
  • Daratumumab
  • +2 more
  • Wichita, Kansas
  • +4 more
Jun 13, 2022

Multiple Myeloma Trial in United States (Elotuzumab, Pomalidomide, Carfilzomib)

Terminated
  • Multiple Myeloma
  • Encinitas, California
  • +5 more
Mar 15, 2022

Plasma Cell Myeloma Trial (Isatuximab (SAR650984), Cemiplimab (SAR439684), Dexamethasone)

Not yet recruiting
  • Plasma Cell Myeloma
  • Isatuximab (SAR650984)
  • +4 more
  • (no location specified)
Feb 1, 2023

Plasma Cell Myeloma Recurrent Trial in Australia, Chile (Isatuximab IV, Isatuximab SC, Dexamethasone)

Recruiting
  • Plasma Cell Myeloma Recurrent
  • Isatuximab IV
  • +3 more
  • Salt Lake City, Utah
  • +33 more
Jan 16, 2023

Multiple Myeloma, Deletion 17P Syndrome Trial in Italy (Daratumumab, Pomalidomide, Dexamethasone)

Active, not recruiting
  • Multiple Myeloma
  • Deletion 17P Syndrome
  • Ancona, Italy
  • +14 more
Mar 24, 2022

Evaluation of POMALYST® Treatment of Multiple Myeloma in Korea

Recruiting
  • Multiple Myeloma
  • POMALYST® (Pomalidomide)
  • Ansan, Korea, Republic of
  • +32 more
Aug 17, 2022

Relapsed, Refractory, Multiple Myeloma Trial in Guangzhou (Pomalidomide, Bendamustine, Dexamethasone)

Not yet recruiting
  • Relapsed, Refractory, Multiple Myeloma
  • Pomalidomide
  • +2 more
  • Guangzhou, Please Select, China
    Sun Yat-sen University Cancer Center
Feb 17, 2021